Page 9 - Expanded Access Protocol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GENEVA, SWITZERLAND / ACCESSWIRE / December 21, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today announced the appointment of Christiaan ("Chris") L.J.J. Stijnen as Chief Commercial Officer (CCO) effective December 21, 2020. Mr. Stijnen will strengthen the management team in all activities pertaining to the commercialization of RLF-100(TM) and other future assets. Mr. Stijnen is a highly experienced pharm...

GENEVA, SWITZERLAND / ACCESSWIRE / December 18, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, announces that all agenda items of yesterday's Extraordinary General Meeting (" EGM") were approved with a large majority (more than 90 percent) of the represented votes. As a result of the exceptional circumstances due to the coronavirus pandemic, the EGM was held without the physical presence of shareholders, repr...

RELIEF THERAPEUTICS Holdings A EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): AGMEGM Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority 18.12.2020 / 07:00 RELIEF THERAPEUTICS Holding AG Approved with Large Majority Geneva, Switzerland, December 18, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (" Relief" or the " Company"), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, announces that all agenda ...

12/18/2020 | Press release | Distributed by Public on 12/18/2020 00:05 Relief Announces Results of Extraordinary General Meeting of RELIEF THERAPEUTICS Holding AG Approved with Large Majority Geneva, Switzerland, December 18, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) ('Relief' or the 'Company'), a biopharmaceutical company with its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, announces that all agenda items of yesterday's Extraordinary General Meeting ('EGM') were approved with a large majority (more than 90 perce...